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Strengths and limitations of this study
 ► Patients with pancreatic cancer are under- 
represented in psychosocial research and this sur-
vey provides important insight into their experiences 
and needs.
 ► Cognitive testing of the questionnaire was undertak-
en with a sample of patients, to maximise consisten-
cy of responses.
 ► The study achieved a good sample size, but gen-
eralisation is limited by the sampling method used.
 ► Recruitment through National Health Service clinics 
was low and most participants were recruited using 
online methods.
 ► The sample over- represented people with resect-
able (better prognosis) disease.
AbStrACt
Objectives Patients diagnosed with pancreatic cancer 
have the poorest survival prognosis of any cancer. This 
survey aimed to describe their experiences of care and 
supportive care needs to inform future service provision.
Design Cross- sectional questionnaire survey of patients 
with pancreatic cancer in the UK.
Setting Individuals at any stage along the care pathway 
were recruited via five National Health Service sites in the 
UK, and online, from January to June 2018.
Participants 274 individuals completed the questionnaire 
(78% (215) were completed online). Approximately 
half of participants were diagnosed within the last year 
(133/274). Of 212 providing gender details, 82 were male 
and 130 were female. Ninety per cent (192/213) described 
themselves as White British.
Primary outcome measures Experiences of 
communication and information; involvement in treatment 
decisions; supportive care needs.
results Communication with, and care received from, 
clinical staff were generally reported positively. However, 
29% (75/260) of respondents did not receive enough 
information at diagnosis, and 10% (25/253) felt they were 
not involved in decisions about their treatment, but would 
have liked to be. Supportive care needs were greatest 
in psychological and physical/daily living domains. 49% 
(108/221) of respondents reported one or more moderate/
high unmet needs within the last month, of which the 
most commonly reported were: dealing with uncertainty 
about the future; fears about the cancer spreading; not 
being able to do things they used to; concerns about those 
close to them; lack of energy; anxiety; feelings of sadness 
and feeling down/depressed. Experiences were poorer, 
and unmet supportive care needs greater, in patients with 
unresectable disease.
Conclusions Patients with pancreatic cancer have 
unmet information and support needs across the cancer 
trajectory. Psychological and physical support appears to 
be the biggest gap in care. Needs should be assessed and 
supportive care interventions implemented from the point 
of diagnosis, and monitored regularly to help patients live 
as good a quality of life as possible.
IntrODuCtIOn
Pancreatic cancer is the 11th most common 
cancer in the UK, accounting for 3% of all new 
cancer cases (2015).1 There are around 9800 
new pancreatic cancer cases in the UK every 
year (2013–2015).1 Around a fifth (21%) of 
people diagnosed with pancreatic cancer 
survive their disease for 1 year or more, and 
only around 3% for 5 years or more.1 Survival 
has shown little improvement in the last 40 
years, and pancreatic cancer is the fifth most 
common cause of cancer death in the UK.1
Poor prognosis results from a combination 
of late diagnosis, aggressive tumour biology, 
complex surgical procedures and a lack of 
effective systemic treatments. Only around 
10%–15% of patients are eligible for tumour 
resection, and approximately 28% of patients 
have chemotherapy as part of their primary 
cancer treatment.2 Newer treatments offer 
optimism, and can help some patients to live 
for many months or even years.3 For most, 
however, supportive care is the mainstay of 
management.
Pancreatic cancer is associated with marked 
symptoms that have a severe impact on quality 
of life. The early identification and pallia-
tion of symptoms is therefore an important 
aspect of patient care. There is evidence to 
suggest that the severity of these symptoms 
can predict prognosis and survival.2 Given 
the nature and prognosis of the disease, it 
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is unsurprising that studies have reported diminished 
quality of life in patients with pancreatic cancer when 
compared with other cancer populations and the general 
population.4 However, the literature on patient experi-
ences of pancreatic cancer is limited.
Patient experience is increasingly recognised as one of 
the central components of healthcare quality, and positive 
associations have been identified between patient experi-
ence, patient safety and clinical effectiveness.5 Therefore, 
it is essential to understand people’s experiences of care 
to inform where there is room for improving care delivery 
and quality. The National Cancer Patient Experience 
Survey has been conducted annually in England since 
2010 to understand and monitor national progress on 
cancer care. However, the survey is generic to all cancer 
types, and samples only those with a hospital inpatient stay 
or day attendance for treatment within a specific 3- month 
sampling period, with invites sent several months later.6 
An examination of non- response to this survey found that 
patients with pancreatic cancer were around five times 
more likely to have died between sampling and survey 
mail- out.7 As a result, the number of patients with pancre-
atic cancer responding to the survey is relatively low, and 
data specific to these patients are not available and are 
instead grouped alongside other cancer types.
There is a clear need for improved understanding of 
the physical and emotional well- being of patients with 
pancreatic cancer, and factors that may help improve their 
quality of life. This study therefore set out to explore the 
care experiences and supportive care needs of patients in 
the UK diagnosed with pancreatic cancer.
MethODS
Design
The study used a cross- sectional survey design. We used 
the Strengthening the Reporting of Observational 
Studies in Epidemiology cross- sectional checklist when 
writing our report.8
Survey development
A draft question set was developed drawing on Picker’s 
existing bank of validated patient experience questions, 
guided by the Principles of Person- Centred Care,9 to 
enquire about experiences of care at the time of diag-
nosis, during treatment and beyond.
With permission from the authors, a modified version 
of the Supportive Care Needs Survey- Short Form (SCNS- SF) 
(34 items)10 11 was incorporated into the questionnaire. It 
measures needs across five domains: psychological; phys-
ical/daily living; health system/information; patient care/
support; sexuality. Participants were asked to score their 
need for help in the last month for each item as either no 
need, need met, low need for help, moderate need for 
help, or high need for help. The SCNS measure is generic 
to all cancers, so while we did not remove any items, we 
included an additional five items specific to pancreatic 
cancer. These were identified in our literature review and 
discussions with clinical experts as being particularly rele-
vant to patients and related to:
 ► Problems with sleeping.
 ► Nausea and vomiting (eg, feeling/being sick).
 ► Digestion problems (eg, bowel problems, bloating, 
wind, discomfort).
 ► Changes to appetite/body weight.
 ► Itchiness.
Standard sociodemographic information was also 
collected.
The cognitive process of responding to the survey 
questions was also considered,12 13 seeking to establish 
consistency in question comprehension, information 
retrieval and response. Thirteen cognitive interviews 
were conducted with patients with a pancreatic cancer 
diagnosis. Minor amendments to the format and instruc-
tion of the SCNS were made following these interviews. 
Comparability was maintained with the original version, 
yet the questions were found by participants to be easier 
to complete once the amendments had been made. In 
addition, some of the patient experience questions were 
reworded for clarity; for example, the question, ‘How do 
you feel about the amount of information you were given 
when first diagnosed’, was changed to, ‘How do you feel 
about the amount of information you were given around 
the time you were diagnosed’. This was in response to 
feedback that patients struggled to recall the conversa-
tion at the exact time of diagnosis.
The final questionnaire addressed the following topic 
areas: experiences of care (communication and informa-
tion); supportive care needs (SCNS- SF+five additional 
items); financial impact of diagnosis; overall quality of life 
and health rating; and demographic details. The ques-
tionnaire also included four open- ended questions where 
participants could add more detail about their responses 
(data not presented). A copy of the questionnaire, and 
the free- text data set, is available on request from the 
authors.
Patient and public involvement
Pancreatic Cancer UK provided comments on the draft 
questionnaire and study design. Thirteen individuals with 
pancreatic cancer, identified with the help of Pancreatic 
Cancer UK and the Oxford University Hospitals Foun-
dation Trust pancreatic cancer team, helped to test the 
questionnaire.
Study population
Anyone aged 18 and over in the UK with a diagnosis of 
pancreatic or ampullary cancer was eligible to take part in 
the survey. A small proportion of patients who are initially 
suspected to have pancreatic cancer eventually prove to 
have ampullary cancer. They are treated similarly.14 The 
authors therefore felt that it was preferable to include 
both diagnoses and acknowledge that a small minority of 
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  Male 82 38.7
  Female 130 61.3
  Missing 62
Age group
  31–50 years 25 11.8
  51–60 years 50 23.7
  61–70 years 82 38.9
  >70 years 54 25.6
  Missing 63
Ethnic group
  White—British 192 90.1
  White—Other 12 5.6
  Other 9 4.2
  Missing 61
Time since diagnosis
  <6 months 82 29.9
  6 months to 2 years 104 38.0
  >2 years 88 32.1
Treatment
  Surgery 29 11.3
  Surgery+chemotherapy 114 44.4
  Chemotherapy 85 33.1
  Surgery and/or chemo planned 7 2.7
  No active treatment 17 6.6
  Treatment plan unknown 5 1.9
  Missing 17
Sampling
Recruitment took place between January and June 2018. 
Five National Health Service (NHS) centres (four in 
England and one in Scotland) distributed questionnaires 
to eligible patients attending oncology clinics during the 
recruitment window. Centres were asked to approach all 
eligible patients and give them brief information about 
the survey and, to those who were interested, a study 
information pack (containing an invitation letter, study 
information sheet, copy of the study questionnaire and a 
reply paid envelope). The approach to patients was made 
by a member of the clinical team, most often the clinical 
nurse specialist.
In addition, an online version of the questionnaire was 
made available. This was promoted by Picker, Oxford 
Brookes University and Pancreatic Cancer UK, using rele-
vant websites and social networks including Twitter, Face-
book and Health Unlocked. Events hosted by Pancreatic 
Cancer UK, and attended by health professionals and 
patients, were also used to publicise the survey.
Consent
As approved by the National Research Ethics Service, 
informed consent was implicit by return of a paper 
completed questionnaire. This was made clear in the 
study information. Consent for the online survey was indi-
cated by a respondent submitting their responses or by 
indicating at the beginning of the survey that their partial 
responses may be used should they not reach the end.
Statistical analysis
The completed paper questionnaires were returned to 
the research team for manual data entry. The online 
questionnaire was created in Snap (version 11). Snap 
WebHost was used to collect online responses. At the end 
of fieldwork, the online data were imported into SPSS 
(V.25) and combined with paper responses. Frequencies 
and proportions were used to summarise questionnaire 
responses. We did not impute values because we were 
unable to reject the hypothesis of missing not at random 
in what was already a non- randomised sample. Instead, we 
used all the data for each individual analysis and provide 
the denominator used in each case. Where appropriate, 
results were cross- tabulated by patients with resectable 
(undergone surgery) and unresectable (had not under-
gone surgery and/or no surgery planned) disease. Indi-
viduals who indicated surgery was planned were removed 
from these analyses. Statistical tests of inference were not 
conducted, as the non- random sample precludes gener-
alisation to the population without bias. CIs (95% CIs) 
for proportions are provided to give insight into differ-
ences within the sample. For analysis of the SCNS- SF34 
questions, the original 34 items were used to calculate 
five domain scores: psychological, physical/daily living, 
health system/information, patient care/support, and 
sexuality. Mean normalised domain scores were calcu-
lated using the SCNS authors’ published procedure.11 
Briefly, this involved assigning a score of 1 (no need) to 5 
(high unmet need) to each SCNS item. The item scores 
are summed for each domain for each person, and the 
normalised score calculated, adjusting for the number of 
questions and maximum response value.
reSultS
Study population
Two hundred and seventy- four completed questionnaires 
were received (215 online; 59 paper). Sample sociode-
mographic and clinical characteristics (self- reported) are 
summarised in table 1. Some participants did not provide 
answers to all demographic questions asked, and indi-
vidual questions were analysed according to the number 
of respondents to those questions. The mean age of 
participants was 64 years. Sixty- one per cent (130/212) 
were female. Forty- nine per cent (133/274) of the sample 
were diagnosed within the last year. Fifty- five per cent 
(143/258) had undergone surgery to remove part of the 
pancreas; 34% (87/258) were not going to have such 
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Table 2 SCNS- SF34 domain scores
Domain score
Total sample* Resectable patients Non- resectable patients
n Mean SD n Mean SD n Mean SD
Psychological 212 31.2 30.6 120 27.8 29.3 67 36.5 33.7
Physical 206 25.6 25.4 117 24.8 24.4 65 28.3 26.8
Information 203 19.7 26.4 114 15.8 23.2 67 25.3 30.6
Care 201 15.9 24.9 114 13.8 22.0 65 20.3 30.4
Sexuality 194 25.9 25.9 112 12.3 26.0 65 12.7 25.9
*The number of missing responses varied by SCNS- SF34 items.
SCNS- SF34, Supportive Care Needs Survey- Short Form (34 items).
surgery, 4% (11/258) reported surgery was planned and 
7% (17/258) did not know if they would undergo surgery.
experiences of communication and information
Most patients reported positive experiences of care. 
Thirty- eight per cent (103/271) of patients felt their diag-
nosis had definitely been given in a sensitive way. Partic-
ipants who had had a pancreatic resection were more 
likely than unresectable patients to feel that their diag-
nosis had definitely been given sensitively (39%; 55/142, 
95% CI 31% to 47% vs 31%; 27/86, 95% CI 22% to 42%).
Over one- quarter of participants felt they had not been 
given enough information around the time of diagnosis 
(29%, 75/260). A greater proportion of unresectable 
patients (37%; 32/87, 95% CI 27% to 42%) than those 
who had had a pancreatic resection (27%; 38/143, 95% 
CI 20% to 34%) responded in this way.
Involvement in treatment decision-making
Ten per cent of all participants (25/253) felt they had 
not been involved in decisions about their treatment and 
care, and would have liked this, with unresectable patients 
more likely than resectable patients to report this (16%; 
13/83, 95% CI 9% to 25% vs 6%; 9/140, 95% CI 3% to 
11%). Less than two- thirds of participants (60%; 164/251) 
responded that staff definitely talked to them about their 
care and treatment in a way they could understand. Fewer 
patients with unresectable disease responded in this way 
(52%; 43/82, 95% CI 42% to 63% vs 72%; 100/139, 95% 
CI 64% to 79%).
Dietary information and therapy
Most participants in this survey reported receiving 
pancreatic enzyme replacement therapy (PERT, 83%; 
214/259). A further 5% (14/259) had been prescribed 
PERT but were not currently taking it. Thirty- three per 
cent (76/228) of participants prescribed PERT felt they 
had received insufficient information about it.
Supportive care needs
The mean normalised domain scores for the SCNS- SF34 
items were highest (indicating a greater need) for the 
psychological and physical/daily living domains (both 
scoring >25), and lower in the information, care and sexu-
ality domains (scores <20) (table 2). For the SCNS- SF34 
items, 86% (190/220) of respondents reported having 
at least one supportive care need, and 48% (105/220) 
reported one or more moderate or high unmet needs. 
Using our extended 39- item version of the SCNS, 87% 
(193/221) of participants reported having one or more 
unmet supportive care needs and 49% (108/221) 
reported one or more moderate or high unmet needs. 
All SCNS scores were higher in unresectable patients 
compared with resectable patients. The 10 individual 
survey items which were most commonly cited as a 
moderate or high unmet need are presented in table 3 
for the overall sample, with the corresponding propor-
tions for resectable and unresectable patients. The level 
of unmet need was greater in the unresectable group. For 
unresectable patients digestion problems (29%; 18/62) 
and feelings about death and dying (27%; 17/63) were 
included in the 10 most commonly reported moderate/
high needs, whereas for the resectable group having 
access to a professional counsellor (18%; 19/105) was 
included (data not shown).
Financial impact
Just over half of participants (52%; 111/214) felt the 
diagnosis of pancreatic cancer had negatively impacted 
on their day- to- day financial situation. Around a third 
(30%; 64/212) of participants had received financial 
advice, which they found useful. However, 28% (59/212) 
needed financial advice or did not find the advice they 
had received to be helpful.
DISCuSSIOn
This study provides valuable information on the care 
experiences and supportive care needs of patients living 
with a diagnosis of pancreatic cancer in the UK. While 
overall patient experiences of care were positive, the 
study highlights some important gaps across the patient 
pathway, including for longer term survivors. Participants 
with unresectable disease expressed greater unmet needs 
and poorer experiences overall than patients who had 
received surgical resection. In the UK, surgical resection 
rates are around 10%–15%,2 and our sample therefore 
considerably over- represented patients with resectable 
disease (56%) and therefore a better prognosis. The 
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Table 3 Most common unmet supportive care needs
Supportive Care Needs Survey items* Total sample Resectable patients† Unresectable patients‡
Uncertainty about the future 31.4% 58/185 28.6% 30/105 37.3% 22/59
Fears about the cancer spreading 30.1% 56/186 29.5% 31/105 33.9% 21/62
Not being able to do the things you used to 25.0% 47/188 27.3% 30/110 24.1% 14/58
Concerns about the worries of those close to 
you
24.7% 47/190 23.4% 26/111 30.7% 19/62
Lack of energy/tiredness 23.5% 44/187 23.4% 26/111 28.1% 16/57
Anxiety 22.4% 43/192 20.9% 23/110 28.3% 17/60
Worry that the results of treatment are beyond 
your control
21.1% 39/185 16.0% 17/106 31.0% 18/58
Feelings of sadness 20.5% 39/190 17.8% 19/107 27.9% 17/61
Being informed about things you can do to help 
yourself feel better
20.4% 39/191 17.3% 19/110 28.6% 18/63
Feeling down or depressed 20.4% 40/196 18.0% 20/111 25.8% 16/62
*The number of missing responses varied by Supportive Care Needs Survey (SCNS) item.
†Patients who were unsure if they would be having a resection or not were excluded.
‡Patients for whom a resection was planned were not included.
findings, thus, clearly indicate considerable room for 
improvement in the delivery of patient- centred care to 
patients diagnosed with pancreatic cancer.
More than one- quarter of participants felt information 
was lacking around the time of diagnosis, and 1 in 10 
participants did not feel involved in decisions about their 
treatment and care, and would have liked to have been. 
This finding is supported by a previous UK- based qualita-
tive study, which explored decision- making experiences 
of patients with pancreatic cancer. Participants reported a 
sense of being pressured to accept treatment, a sense that 
in a life- threatening situation there are no ‘real options’, 
and reported the confusion that can be caused when 
clinical opinions differ.15 Another study highlighted that 
the patient’s perceived level of involvement in decision- 
making depended on the quality of information, commu-
nication and involvement during the care period.16
One- third of participants felt they had received insuffi-
cient information about PERT. This finding is concerning 
given that enzyme supplementation, when taken correctly, 
helps prevent weight loss and improve quality and dura-
tion of survival.17 It is recommended for the majority of 
patients.18 A previous qualitative study also reported poor 
understanding of the impact of advanced pancreatic 
cancer on digestion, a lack of awareness of potential inter-
ventions to treat pancreatic exocrine insufficiency and a 
lack of understanding about the symptoms of pancreatic 
exocrine insufficiency on the part of the participants.19
In relation to supportive care needs, we found needs 
were greatest in the psychological and physical/daily 
living domains, concurring with the findings of a recent 
review of the unmet needs of patients with advanced 
cancer.20 Correspondingly, psychological concerns were 
prominent in the most commonly reported individual 
moderate or high unmet need, including: dealing with 
uncertainty, fear of progression of cancer, concerns about 
family members and feelings of sadness or depression. 
Lack of energy and not being able to do the things they 
used to do were commonly reported physical unmet 
needs. Interestingly, the five additional pancreatic cancer- 
specific items we included did not emerge in the 10 most 
common moderate/high unmet needs for the overall 
sample, although digestion problems were included in 
the top 10 for patients with unresectable disease.
Our findings regarding supportive care needs differ 
in some respects from a previous Australian study, which 
also used the SCNS- SF34 to explore the unmet needs of 
patients with pancreatic cancer.21 Overall, they found a 
higher level of supportive care needs and whereas we 
found the scores to be highest for the psychological 
domain they found the highest score for the physical/
daily living domain, followed by the psychological, health 
system/information and patient care domains, which 
all scored equally. They also found 69% of respondents 
reporting at least one moderate to high unmet need. 
However, the median time from diagnosis of study partici-
pants was 3 months, whereas 70% of our respondents were 
diagnosed more than 6 months ago, which may explain 
this difference in findings. Nonetheless, 6 of the top 10 
reported moderate to high unmet individual needs items 
were the same.
The findings from our study suggest that despite the 
recommended introduction of holistic needs assessment 
and survivorship care planning to cancer care services,22 
the psychological aspects of being diagnosed with pancre-
atic cancer are not being adequately addressed in the 
UK. Recent guidance on the diagnosis and manage-
ment of pancreatic cancer18 highlights the importance of 
assessing for and supporting the management of psycho-
logical distress. However, many services are stretched and 
do not have the resources in terms of manpower or skills 
to address psychological concerns. In some centres, there 
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are very limited psychological services available. In other 
centres, the waiting list may be long and thus problem-
atic for patients with a poor prognosis disease. Referral to 
psychological services provided in the community (in the 
UK, via the Improving Access to Psychological Therapies 
programme23), and signposting to charity counselling and 
advice services could be helpful for some patients and 
carers.
There are few psychosocial intervention studies in the 
literature targeting patients with pancreatic cancer. A 
small pilot study trialled an interdisciplinary supportive 
care planning intervention comprising quality of life 
assessment, case presentation at interdisciplinary care 
meeting and two nurse- administered educational sessions 
addressing quality of life concerns.24 Patients found the 
intervention useful but further work is needed to confirm 
this. A previous study has indicated that a home- based 
walking programme with regular self- monitoring was 
feasible, safe and significantly improved fatigue, phys-
ical functioning and quality of life compared with usual 
care,25 although again further research in this area is 
needed. A survey of survivors treated for resectable 
pancreatic cancer in the USA found that over two- thirds 
of patients expressed interest in exercise and diet inter-
vention programmes.26
Our study has also indicated the level of concern 
patients have about those close to them, and previous 
research has indicated the health of caregivers is dimin-
ished.27 The development of interventions to support 
caregivers as well as patients is therefore important.
Strengths and weaknesses
Patients with pancreatic cancer are very under- 
represented in psychosocial research. The nature and 
prognosis of the disease makes this a hard- to- reach patient 
group, yet one with potentially huge needs. This survey 
provides responses from 274 individuals in the UK and 
gives important insight into the experiences and needs 
of people affected by pancreatic cancer. However, our 
sample cannot be considered representative of the pancre-
atic cancer patient population in the UK. Response to 
recruitment through NHS clinics was low. Online recruit-
ment was much more successful, but introduced greater 
potential for selection bias. The proportion of resected 
patients (who have a better prognosis) in our sample is 
much higher than the national average. Related to this, 
almost one- third of our sample received their diagnosis 
more than 2 years ago whereas Public Health England’s 
National Cancer Registration and Analysis Service for the 
period 2006–2015 indicates a 2- year survival in only 11% 
of patients and 3- year survival in 8% of patients. However, 
our findings provide novel and valuable data on longer 
term survivors with pancreatic cancer.
COnCluSIOn
Patients with pancreatic cancer have unmet informa-
tion, communication and support needs across the 
cancer trajectory, particularly those with unresectable 
disease. Needs should be assessed, and supportive care 
interventions implemented from the point of diagnosis, 
with regular monitoring thereafter to help patients with 
pancreatic cancer live as good a quality of life as possible. 
Psychological support emerged as an important gap in 
care, and interventions to provide psychological support 
to patients and their families are required. The use of 
qualitative research methods and potentially the inclu-
sion of carers as well as patients in future research would 
further our understanding of patient needs and the types 
of intervention that would be most useful.
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